Celanese Corporation, a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, an independent European antisense drug discovery and development company, have entered a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).   ASOs are synthetic molecules designed to target specific messenger RNA to prevent the production of proteins implicated in the progression of a wide range of diseases inclu...